Thiotepa: alkylating agent for chemotherapy

Tepadina (thiotepa) is a cytotoxic treatment for haematological disease and solid tumours. It is approved for use alongside other forms of chemotherapy in preparation for allogeneic or autologous haematopoietic progenitor cell transplantation.

Thiotepa acts as an alkylating agent. It has efficacy in a variety of malignancies, including lymphoma and myeloma, breast and ovarian cancer and tumours of the central nervous system and germ cells. Treatment must be supervised by a specialist.

View Tepadina drug record

Further information: Intrapharm

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Don't treat subclinical hypothyroidism, prescribers advised

Don't treat subclinical hypothyroidism, prescribers advised

GPs should monitor patients with subclinical hypothyroidism...

Refresh your knowledge on prescribing in pregnancy with MIMS Learning

Refresh your knowledge on prescribing in pregnancy with MIMS Learning

MIMS Learning is offering a new interactive module,...

Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Antidiabetic Agents, Use in Renal Impairment

Antidiabetic Agents, Use in Renal Impairment

Dosing of diabetes drugs in patients with renal impairment.